Added to YB: 2025-11-11
Pitch date: 2025-11-07
CLPT [neutral]
ClearPoint Neuro, Inc.
-29.43%
current return
Author Info
MVC Investing is a long-term investor. BSc in Economics, MSc in Finance. Equity Analyst with a focus on Fundamental Analysis and Valuation. Sign up for the newsletter.
Company Info
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States.
Market Cap
$365.6M
Pitch Price
$16.58
Price Target
N/A
Dividend
N/A
EV/EBITDA
-17.88
P/E
-12.07
EV/Sales
9.69
Sector
Health Care Equipment and Supplies
Category
growth
ClearPoint Neuro (CLPT): Q3 Earnings Review
CLPT (earnings): Q3 rev $8.9M (+9% YoY) vs $9.6M est, narrowed FY25 guidance to $36-38M. AMT-130 gene therapy hit FDA setback after promising data, uncertainty returns. Acquiring IRRAS for $5M cash + 1.325M shares (4.7% dilution), targeting $0.5B hemorrhage market. Thesis intact but commercialization timeline unclear.
Read full article (9 min)